We are live on ! Find out more
NDRM

NeuroDerm Ltd. Ordinary Shares
NDRM

Delisted

NDRM was delisted on the 17th of October, 2017.

Back to rankings

50 hedge funds and large institutions have $134M invested in NeuroDerm Ltd. Ordinary Shares in 2016 Q1 according to their latest regulatory filings, with 11 funds opening new positions, 19 increasing their positions, 12 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

58% more repeat investments, than reductions

Existing positions increased: 19 | Existing positions reduced: 12

10% more first-time investments, than exits

New positions opened: 11 | Existing positions closed: 10

2% more funds holding

Funds holding: 49 → 50 (+1)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

10% less capital invested

Capital invested by funds: $149M → $134M (-$15.1M)

100% less call options, than puts

Call options by funds: $0 | Put options by funds: $1.14M

Holders
50
Holders Change
+1
Holders Change %
+2.04%
% of All Funds
1.33%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
11
Increased
19
Reduced
12
Closed
10
Calls
–
Puts
$1.14M
Net Calls
-$1.14M
Net Calls Change
+$1.06M

Top Buyers

Rank Fund Capital Flow
1
SCM
Scopia Capital Management
New York
+$8.57M
2
ACP
Acuta Capital Partners
California
+$4.72M
3
MMH
Menora Mivtachim Holdings
Israel
+$2.58M
4
SFM
Sphera Funds Management
Israel
+$2.25M
5
B
Bailard
California
+$1.17M

Top Sellers

Rank Fund Capital Flow
1
RG
Redmile Group
California
-$5.52M
2
GC
GMT Capital
Georgia
-$3.23M
3
Acadian Asset Management
Acadian Asset Management
Massachusetts
-$2.62M
4
BIM
Bogle Investment Management
Massachusetts
-$755K
5
UOC
UBS O'Connor
Illinois
-$682K
Name Holding Trade Value Shares
Change 		Change in
Stake
SCM
1
Scopia Capital Management
New York
$47.8M +$8.57M +634,321 +23%
RG
2
Redmile Group
California
$16.7M -$5.52M -408,374 -26%
ACP
3
Acuta Capital Partners
California
$11.7M +$4.72M +349,499 +73%
GC
4
GMT Capital
Georgia
$9.38M -$3.23M -238,900 -26%
ACA
5
Avoro Capital Advisors
New York
$7.59M +$236K +17,455 +3%
BFA
6
BlackRock Fund Advisors
California
$4.83M +$1.04M +77,078 +29%
BBA
7
Baker Bros. Advisors
New York
$4.31M – – –
FCMI
8
Foresite Capital Management III
California
$4.13M +$411K +30,426 +12%
PA
9
Perceptive Advisors
New York
$3.81M – – –
SAM
10
Senzar Asset Management
New York
$3.04M +$185K +13,700 +7%
MMH
11
Menora Mivtachim Holdings
Israel
$2.69M +$2.58M +190,724 New
SFM
12
Sphera Funds Management
Israel
$2.35M +$2.25M +166,359 New
ACH
13
ArrowMark Colorado Holdings
Colorado
$2.25M +$381K +28,198 +22%
RCM
14
RA Capital Management
Massachusetts
$2.04M – – –
FCMI
15
Foresite Capital Management II
California
$1.69M +$865K +64,002 +115%
Goldman Sachs
16
Goldman Sachs
New York
$1.47M +$230K +16,995 +19%
MC
17
Menta Capital
California
$1.35M +$655K +48,453 +102%
B
18
Bailard
California
$1.22M +$1.17M +86,500 New
NC
19
Nexthera Capital
New York
$988K +$297K +22,000 +46%
FHAM
20
Folger Hill Asset Management
New York
$931K – – –
OM
21
Opaleye Management
Massachusetts
$544K +$520K +38,500 New
BIT
22
BlackRock Institutional Trust
California
$419K +$25.2K +1,862 +7%
Acadian Asset Management
23
Acadian Asset Management
Massachusetts
$405K -$2.62M -194,037 -87%
AA
24
ALPS Advisors
Colorado
$342K -$56.1K -4,152 -15%
PPA
25
Parametric Portfolio Associates
Washington
$326K +$312K +23,089 New
1
2 3

NDRM Hedge Fund Activity: Q1 2016 in Review

50 of the 3,753 institutional investors tracked by Wall St. Rank reported a position in NeuroDerm Ltd. Ordinary Shares (NDRM) for Q1 2016, worth a combined $134M — down 10% from $149M a quarter earlier.

Buyers outnumbered sellers: 11 funds opened new NDRM positions and 10 closed out — a net gain of 1 holder — while 19 added to existing stakes and 12 trimmed.

The largest buyer was Scopia Capital Management, adding an estimated $8.57M. The largest seller was Redmile Group, cutting an estimated $5.52M.

  • 50 institutional investors held NeuroDerm Ltd. Ordinary Shares (NDRM) as of Q1 2016, up from 49 in Q4 2015.
  • Funds reported $134M of NeuroDerm Ltd. Ordinary Shares stock for Q1 2016, down 10% quarter-over-quarter.
  • 11 funds opened new NeuroDerm Ltd. Ordinary Shares positions in Q1 2016 and 10 closed out, a net change of +1 holder.
  • The largest NeuroDerm Ltd. Ordinary Shares buyer in Q1 2016 was Scopia Capital Management, an estimated $8.57M added.
  • The largest NeuroDerm Ltd. Ordinary Shares seller in Q1 2016 was Redmile Group, an estimated $5.52M sold.

Based on aggregated 13F filings for Q1 2016.